NEOGEN CORP (NEOG) Fundamental Analysis & Valuation

NASDAQ:NEOG • US6404911066

9.7 USD
-0.99 (-9.26%)
At close: Mar 6, 2026
9.7 USD
0 (0%)
After Hours: 3/6/2026, 8:00:02 PM

This NEOG fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

3

NEOG gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 184 industry peers in the Health Care Equipment & Supplies industry. NEOG scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. NEOG does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

2

1. NEOG Profitability Analysis

1.1 Basic Checks

  • In the past year NEOG was profitable.
  • In the past year NEOG had a positive cash flow from operations.
  • In multiple years NEOG reported negative net income over the last 5 years.
  • NEOG had a positive operating cash flow in each of the past 5 years.
NEOG Yearly Net Income VS EBIT VS OCF VS FCFNEOG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -200M -400M -600M -800M -1B

1.2 Ratios

  • NEOG's Return On Assets of -17.94% is in line compared to the rest of the industry. NEOG outperforms 53.26% of its industry peers.
  • Looking at the Return On Equity, with a value of -28.64%, NEOG is in line with its industry, outperforming 54.89% of the companies in the same industry.
Industry RankSector Rank
ROA -17.94%
ROE -28.64%
ROIC N/A
ROA(3y)-10.81%
ROA(5y)-4.19%
ROE(3y)-17.92%
ROE(5y)-8.21%
ROIC(3y)N/A
ROIC(5y)N/A
NEOG Yearly ROA, ROE, ROICNEOG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -20 -40

1.3 Margins

  • The Gross Margin of NEOG (45.98%) is worse than 60.87% of its industry peers.
  • NEOG's Gross Margin has been stable in the last couple of years.
  • NEOG does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 45.98%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.72%
GM growth 5Y0.07%
NEOG Yearly Profit, Operating, Gross MarginsNEOG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 -100

4

2. NEOG Health Analysis

2.1 Basic Checks

  • NEOG does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for NEOG remains at a similar level compared to 1 year ago.
  • The number of shares outstanding for NEOG has been increased compared to 5 years ago.
  • The debt/assets ratio for NEOG is higher compared to a year ago.
NEOG Yearly Shares OutstandingNEOG Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M
NEOG Yearly Total Debt VS Total AssetsNEOG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B

2.2 Solvency

  • Based on the Altman-Z score of 1.18, we must say that NEOG is in the distress zone and has some risk of bankruptcy.
  • The Altman-Z score of NEOG (1.18) is comparable to the rest of the industry.
  • NEOG has a Debt/Equity ratio of 0.38. This is a healthy value indicating a solid balance between debt and equity.
  • Looking at the Debt to Equity ratio, with a value of 0.38, NEOG is in line with its industry, outperforming 47.83% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.38
Debt/FCF N/A
Altman-Z 1.18
ROIC/WACCN/A
WACC10.09%
NEOG Yearly LT Debt VS Equity VS FCFNEOG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 1B 2B 3B

2.3 Liquidity

  • A Current Ratio of 3.91 indicates that NEOG has no problem at all paying its short term obligations.
  • NEOG has a better Current ratio (3.91) than 65.22% of its industry peers.
  • NEOG has a Quick Ratio of 2.80. This indicates that NEOG is financially healthy and has no problem in meeting its short term obligations.
  • NEOG has a better Quick ratio (2.80) than 63.04% of its industry peers.
Industry RankSector Rank
Current Ratio 3.91
Quick Ratio 2.8
NEOG Yearly Current Assets VS Current LiabilitesNEOG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

3

3. NEOG Growth Analysis

3.1 Past

  • NEOG shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -27.50%.
  • NEOG shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -10.20% yearly.
  • NEOG shows a decrease in Revenue. In the last year, the revenue decreased by -3.67%.
  • The Revenue has been growing by 16.43% on average over the past years. This is quite good.
EPS 1Y (TTM)-27.5%
EPS 3Y-9.82%
EPS 5Y-10.2%
EPS Q2Q%-9.09%
Revenue 1Y (TTM)-3.67%
Revenue growth 3Y19.28%
Revenue growth 5Y16.43%
Sales Q2Q%-2.84%

3.2 Future

  • Based on estimates for the next years, NEOG will show a small growth in Earnings Per Share. The EPS will grow by 7.29% on average per year.
  • The Revenue is expected to decrease by -0.50% on average over the next years.
EPS Next Y-9.33%
EPS Next 2Y1.38%
EPS Next 3Y9.52%
EPS Next 5Y7.29%
Revenue Next Year-4.55%
Revenue Next 2Y-1.49%
Revenue Next 3Y-0.67%
Revenue Next 5Y-0.5%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
NEOG Yearly Revenue VS EstimatesNEOG Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M 800M
NEOG Yearly EPS VS EstimatesNEOG Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.2 0.4 0.6

2

4. NEOG Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 33.45, NEOG can be considered very expensive at the moment.
  • Compared to the rest of the industry, the Price/Earnings ratio of NEOG indicates a somewhat cheap valuation: NEOG is cheaper than 72.28% of the companies listed in the same industry.
  • Compared to an average S&P500 Price/Earnings ratio of 26.29, NEOG is valued a bit more expensive.
  • NEOG is valuated quite expensively with a Price/Forward Earnings ratio of 28.60.
  • NEOG's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. NEOG is cheaper than 72.28% of the companies in the same industry.
  • When comparing the Price/Forward Earnings ratio of NEOG to the average of the S&P500 Index (24.60), we can say NEOG is valued inline with the index average.
Industry RankSector Rank
PE 33.45
Fwd PE 28.6
NEOG Price Earnings VS Forward Price EarningsNEOG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of NEOG indicates a somewhat cheap valuation: NEOG is cheaper than 68.48% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 31.23
NEOG Per share dataNEOG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y1.38%
EPS Next 3Y9.52%

0

5. NEOG Dividend Analysis

5.1 Amount

  • No dividends for NEOG!.
Industry RankSector Rank
Dividend Yield 0%

NEOG Fundamentals: All Metrics, Ratios and Statistics

NEOGEN CORP

NASDAQ:NEOG (3/6/2026, 8:00:02 PM)

After market: 9.7 0 (0%)

9.7

-0.99 (-9.26%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)01-08
Earnings (Next)04-01
Inst Owners104.06%
Inst Owner Change-16.56%
Ins Owners0.65%
Ins Owner Change24.72%
Market Cap2.11B
Revenue(TTM)880.32M
Net Income(TTM)-602.74M
Analysts78.18
Price Target11.22 (15.67%)
Short Float %4.85%
Short Ratio2.9
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)87.17%
Min EPS beat(2)78.25%
Max EPS beat(2)96.08%
EPS beat(4)2
Avg EPS beat(4)32.2%
Min EPS beat(4)-34.64%
Max EPS beat(4)96.08%
EPS beat(8)3
Avg EPS beat(8)11.3%
EPS beat(12)5
Avg EPS beat(12)119.18%
EPS beat(16)6
Avg EPS beat(16)37.27%
Revenue beat(2)2
Avg Revenue beat(2)3.22%
Min Revenue beat(2)0.46%
Max Revenue beat(2)5.99%
Revenue beat(4)2
Avg Revenue beat(4)0.6%
Min Revenue beat(4)-3.66%
Max Revenue beat(4)5.99%
Revenue beat(8)3
Avg Revenue beat(8)0.18%
Revenue beat(12)4
Avg Revenue beat(12)-0.24%
Revenue beat(16)4
Avg Revenue beat(16)-0.78%
PT rev (1m)0%
PT rev (3m)44.26%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-20.69%
EPS NY rev (1m)0%
EPS NY rev (3m)22.22%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)2.17%
Revenue NY rev (1m)0%
Revenue NY rev (3m)3.31%
Valuation
Industry RankSector Rank
PE 33.45
Fwd PE 28.6
P/S 2.4
P/FCF N/A
P/OCF 31.87
P/B 1
P/tB N/A
EV/EBITDA 31.23
EPS(TTM)0.29
EY2.99%
EPS(NY)0.34
Fwd EY3.5%
FCF(TTM)-0.08
FCFYN/A
OCF(TTM)0.3
OCFY3.14%
SpS4.05
BVpS9.67
TBVpS-1.38
PEG (NY)N/A
PEG (5Y)N/A
Graham Number7.95
Profitability
Industry RankSector Rank
ROA -17.94%
ROE -28.64%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 45.98%
FCFM N/A
ROA(3y)-10.81%
ROA(5y)-4.19%
ROE(3y)-17.92%
ROE(5y)-8.21%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.72%
GM growth 5Y0.07%
F-Score4
Asset Turnover0.26
Health
Industry RankSector Rank
Debt/Equity 0.38
Debt/FCF N/A
Debt/EBITDA 8.98
Cap/Depr 71.99%
Cap/Sales 9.62%
Interest Coverage N/A
Cash Conversion 74.97%
Profit Quality N/A
Current Ratio 3.91
Quick Ratio 2.8
Altman-Z 1.18
F-Score4
WACC10.09%
ROIC/WACCN/A
Cap/Depr(3y)85.8%
Cap/Depr(5y)97.5%
Cap/Sales(3y)10.58%
Cap/Sales(5y)8.42%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-27.5%
EPS 3Y-9.82%
EPS 5Y-10.2%
EPS Q2Q%-9.09%
EPS Next Y-9.33%
EPS Next 2Y1.38%
EPS Next 3Y9.52%
EPS Next 5Y7.29%
Revenue 1Y (TTM)-3.67%
Revenue growth 3Y19.28%
Revenue growth 5Y16.43%
Sales Q2Q%-2.84%
Revenue Next Year-4.55%
Revenue Next 2Y-1.49%
Revenue Next 3Y-0.67%
Revenue Next 5Y-0.5%
EBIT growth 1Y-193.85%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year138.34%
EBIT Next 3Y34.61%
EBIT Next 5Y20.01%
FCF growth 1Y-209.2%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-41.22%
OCF growth 3Y-5.05%
OCF growth 5Y-7.47%

NEOGEN CORP / NEOG FAQ

What is the fundamental rating for NEOG stock?

ChartMill assigns a fundamental rating of 3 / 10 to NEOG.


What is the valuation status of NEOGEN CORP (NEOG) stock?

ChartMill assigns a valuation rating of 2 / 10 to NEOGEN CORP (NEOG). This can be considered as Overvalued.


How profitable is NEOGEN CORP (NEOG) stock?

NEOGEN CORP (NEOG) has a profitability rating of 2 / 10.


What is the financial health of NEOGEN CORP (NEOG) stock?

The financial health rating of NEOGEN CORP (NEOG) is 4 / 10.


What is the expected EPS growth for NEOGEN CORP (NEOG) stock?

The Earnings per Share (EPS) of NEOGEN CORP (NEOG) is expected to decline by -9.33% in the next year.